Cancer Genetics and Epigenetics, 2025, Vol.13, No.2, 50-61 http://medscipublisher.com/index.php/cge 56 6.2 Methods of coordination between surgery and radiotherapy Surgical resection of the tumor remains the foundation of the treatment for advanced ovarian cancer, and combining it with individualized treatment is the key to optimizing the outcome. The amount of residual tumor after surgery is highly related to the effect of subsequent chemotherapy and the overall survival time, which makes the selection of appropriate patients and surgical plans an important part of individualized treatment (Nick et al., 2015). Preoperative assessment tools and methods are being developed to identify patients who can benefit the most from complete tumor resection and further individualize surgical care (Nick et al., 2015). Although radiotherapy is not commonly used in the treatment of ovarian cancer, researchers are exploring new combination strategies to combine it with targeted drugs and immunotherapy in the hope of exerting potential synergistic effects. Meanwhile, various rehabilitation programs including exercise, nutritional support and psychological counseling are also under research, aiming to reduce postoperative complications and promote the recovery of patients. This indicates the importance of incorporating supportive care measures into individualized treatment plans (Diaz-Feijoo et al., 2022). 6.3 The role of multidisciplinary teams (MDT) in the treatment plan Integrating personalized treatment into multiple treatment methods is a very complex process, which also reflects the importance of multidisciplinary teams (MDTs) in the treatment of ovarian cancer. The multidisciplinary team is composed of various experts such as gynecological oncologists, internal medicine oncologists, pathologists, and radiologists. They jointly analyzed the results of genetic testing, evaluated the feasibility of the surgery, and formulated personalized treatment plans suitable for the patients, pursuing both good therapeutic effects and taking into account the quality of life of the patients (Bookman, 2016; Kuroki and Guntupalli, 2020). This way of teamwork can ensure that both the patient's condition and personal circumstances are taken into comprehensive consideration when planning the treatment plan. Multidisciplinary teams also contribute to the faster application of new therapies, encourage patients to participate in clinical trials, and enable patients to benefit from the latest achievements of personalized medicine in a timely manner (Bookman, 2016). By coordinating the treatment work of different departments and formulating strategies in combination with the latest scientific research results, multidisciplinary teams are indispensable for providing comprehensive and patient-demand-centered treatment management for patients with advanced ovarian cancer (Kuroki and Guntupalli, 2020). 7 Evaluation of Safety and Health Economics 7.1 Management of adverse events in individualized treatment Compared with traditional chemotherapy methods, individualized treatment for advanced ovarian cancer, such as the use of PARP inhibitors and anti-VEGF monoclonal antibodies, is generally safer. However, some specific adverse reactions may still occur and need to be dealt with carefully (Guan and Lu, 2018; Guy et al., 2022). The use of PARP inhibitors often leads to blood-related problems, such as anemia, leukopenia, thrombocytopenia, and symptoms of gastrointestinal discomfort. However, anti-VEGF drugs may cause elevated blood pressure, proteinuria, and increase the risk of thrombosis. Early detection of these adverse reactions and timely intervention measures are crucial for patients to adhere to treatment and achieve better therapeutic effects. Judging from the safety data obtained from clinical trials and comprehensive studies, although most adverse reactions can be controlled, the standards for recording and classifying these reactions vary among different studies, which highlights the importance of unified monitoring standards. Formulating specialized response plans based on the conditions of each patient, including adjusting the dosage of medication and providing supportive care, is very necessary to reduce the side effects of drugs and enable patients to continuously benefit from the treatment (Guan and Lu, 2018; Guy et al., 2022). 7.2 Cost-effectiveness and current situation of insurance coverage The wide application of individualized treatment has brought about difficulties in terms of cost-effectiveness and medical insurance reimbursement. Although targeted drugs and immunotherapy can prolong the stabilization time
RkJQdWJsaXNoZXIy MjQ4ODYzNA==